Fig. 5: Readouts of vaccine efficacy.
a–e Pathology scores (PA) at necropsy per treatment group in arbitrary units. a Total lung score (Lungtot); b primary lung lobe score (Lungpr: the lobe where the inoculum was instilled); c secondary lung lobe score (Lungsec: remaining 6 lung lobes, added up as a measure of pulmonary dissemination); d lung draining (bronchoalveolar) LN score (BaLN), and e total PA scores (PAtot: all PA scores added together). f–j The mycobacterial burden was enumerated by serial, quantitative plating of tissue sample homogenates and calculated for f Lungtot; g Lungpr; h Lungsec; i BaLN, and j spleen. k–o Total lung [18F]-FDG uptake was measured by PET–CT along the infection phase and is expressed here as SUVtotal (total standardized uptake value): k at WK04 (significance compared to Non-v control is indicated by magenta double asterisk above the x-axis); l WK08; m WK12 relative to infectious challenge. Disease progression is shown by plotting the difference in SUV values n from WK4 to 8 (∆WK8-4) and o from WK8 to 12 (∆WK12-8). The number just above the x-axis indicates the number of images not obtained at that point in time due to human endpoint (he) or technical failure (#). Mann–Whitney tests were performed to compare complete parenteral immunization versus complete mucosal immunization (CCIMMIM versus CCAEMAE). Significance is indicated by connecting lines in magenta (*p < 0.05; **p < 0.01).
